braf: the first prevalent oncogene target to show single-agent responsiveness
Published 10 years ago • 13 plays • Length 32:30Download video MP4
Download video MP3
Similar videos
-
32:30
braf: the first prevalent oncogene target to show single-agent responsiveness
-
21:11
resistance to mapk pathway inhibition in braf mutant colorectal cancers
-
3:03
braf: from gene to cancer therapy
-
47:45
resistance in braf and kras mutant cancers
-
5:14
braf mutations across cancers
-
15:57
braf mutation – what does it mean? what are the complications of braf inhibitors?
-
8:24
management of side effects for braf/mek inhibitors for melanoma
-
5:19
how is braf testing done?
-
0:30
dr. infante talks about braf mutation testing
-
22:44
braf targeted therapy - melanoma education symposium, peter boasberg md
-
3:03
what is the importance of combination therapies for braf?
-
1:09
rationale for mek/braf combinations in melanoma
-
1:43
why is it so important to know if you have braf-v600e?
-
0:26
false: “i am braf negative. that means i am going to be okay.”
-
1:01:29
new rules for sequential care in braf-mutated melanoma
-
1:05
covalent-101: bmf-219 in patients with r/r aml, dlbcl & multiple myeloma
-
2:10
combined treatment with braf and mek inhibitors in metastatic melanomas with braf mutations
-
1:22
braf mutations and mek inhibitors
-
1:16
evaluating the prevalence of braf v600e mutations in glioblastoma
-
1:48
dr. brahmer discusses frontline single-agent pembrolizumab in lung cancer
-
0:47
dr. diamond on the ability to test urine for braf mutations
-
1:30
molecular testing in stage 3 melanoma